JP4541645B2 - Ｉ型癌の診断および治療 - Google Patents

Ｉ型癌の診断および治療 Download PDF

Info

Publication number
JP4541645B2
JP4541645B2 JP2002582281A JP2002582281A JP4541645B2 JP 4541645 B2 JP4541645 B2 JP 4541645B2 JP 2002582281 A JP2002582281 A JP 2002582281A JP 2002582281 A JP2002582281 A JP 2002582281A JP 4541645 B2 JP4541645 B2 JP 4541645B2
Authority
JP
Japan
Prior art keywords
cells
cancer
nucleic acid
scn5a
vgsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002582281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533239A (ja
Inventor
ジェイムズ・ケネス・ジョゼフ・ディス
ラウル・チャールズ・コームズ
ムスタファ・ビルギン・アリ・ジャムゴズ
スコット・ペイトン・フレイサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Ip2ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ip2ipo Innovations Ltd filed Critical Ip2ipo Innovations Ltd
Publication of JP2004533239A publication Critical patent/JP2004533239A/ja
Application granted granted Critical
Publication of JP4541645B2 publication Critical patent/JP4541645B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2002582281A 2001-04-12 2002-04-11 Ｉ型癌の診断および治療 Expired - Fee Related JP4541645B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28329501P 2001-04-12 2001-04-12
PCT/GB2002/001692 WO2002083945A2 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: i

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009239422A Division JP2010063458A (ja) 2001-04-12 2009-10-16 Ｉ型癌の診断および治療

Publications (2)

Publication Number Publication Date
JP2004533239A JP2004533239A (ja) 2004-11-04
JP4541645B2 true JP4541645B2 (ja) 2010-09-08

Family

ID=23085371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002582281A Expired - Fee Related JP4541645B2 (ja) 2001-04-12 2002-04-11 Ｉ型癌の診断および治療
JP2009239422A Pending JP2010063458A (ja) 2001-04-12 2009-10-16 Ｉ型癌の診断および治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009239422A Pending JP2010063458A (ja) 2001-04-12 2009-10-16 Ｉ型癌の診断および治療

Country Status (7)

Country Link
US (3) US7393657B2 (enExample)
EP (2) EP1377680B1 (enExample)
JP (2) JP4541645B2 (enExample)
AT (1) ATE527375T1 (enExample)
AU (3) AU2002244862B2 (enExample)
CA (1) CA2443968A1 (enExample)
WO (1) WO2002083945A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300108B1 (en) * 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
US6892099B2 (en) 2001-02-08 2005-05-10 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US8251986B2 (en) 2000-08-17 2012-08-28 Angiodynamics, Inc. Method of destroying tissue cells by eletroporation
US6697670B2 (en) 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
USRE42016E1 (en) 2001-08-13 2010-12-28 Angiodynamics, Inc. Apparatus and method for the treatment of benign prostatic hyperplasia
US7130697B2 (en) * 2002-08-13 2006-10-31 Minnesota Medical Physics Llc Apparatus and method for the treatment of benign prostatic hyperplasia
US6994706B2 (en) * 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US7659082B2 (en) * 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US20050171574A1 (en) 2003-12-24 2005-08-04 The Regents Of The University Of California Electroporation to interrupt blood flow
US8298222B2 (en) 2003-12-24 2012-10-30 The Regents Of The University Of California Electroporation to deliver chemotherapeutics and enhance tumor regression
WO2005069969A2 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
JP4443278B2 (ja) * 2004-03-26 2010-03-31 テルモ株式会社 拡張体付カテーテル
US20060264752A1 (en) * 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
US20060293731A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating tumors using electroporation
US20060293725A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating fatty tissue sites using electroporation
US8114070B2 (en) * 2005-06-24 2012-02-14 Angiodynamics, Inc. Methods and systems for treating BPH using electroporation
US20060293730A1 (en) 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating restenosis sites using electroporation
US20070156135A1 (en) * 2006-01-03 2007-07-05 Boris Rubinsky System and methods for treating atrial fibrillation using electroporation
EP2076313A4 (en) * 2006-10-16 2012-07-25 Univ California GELE WITH PRE-DEFINED CONDUCTIVITY FOR THE FINAL ELECTROPORATION OF A TISSUE
US20080132885A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Methods for treating tissue sites using electroporation
US20080132884A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Systems for treating tissue sites using electroporation
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
BRPI0817393A2 (pt) * 2007-11-19 2015-03-31 Genentech Inc Anticorpo monoclonal, polipetídeo solúvel isolado, método de inibição do progresso de tumores, método de inibição de emt em células e método de determinação se um tumor reagirá a um antagonista de b2 ou um antagonista de notch
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
WO2009121017A1 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Balloon catheter for reducing restenosis via irreversible electroporation
US20100004623A1 (en) * 2008-03-27 2010-01-07 Angiodynamics, Inc. Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US12697172B2 (en) 2008-04-29 2026-08-04 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US8926606B2 (en) * 2009-04-09 2015-01-06 Virginia Tech Intellectual Properties, Inc. Integration of very short electric pulses for minimally to noninvasive electroporation
EP2280741A4 (en) 2008-04-29 2012-06-13 Virginia Tech Intell Prop IRREVERSIBLE ELECTROPORATION FOR THE PRODUCTION OF TISSUE OBJECTS
US10448989B2 (en) 2009-04-09 2019-10-22 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US20090281477A1 (en) 2008-05-09 2009-11-12 Angiodynamics, Inc. Electroporation device and method
US9173704B2 (en) * 2008-06-20 2015-11-03 Angiodynamics, Inc. Device and method for the ablation of fibrin sheath formation on a venous catheter
US9681909B2 (en) * 2008-06-23 2017-06-20 Angiodynamics, Inc. Treatment devices and methods
US20100152725A1 (en) * 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
WO2010085765A2 (en) * 2009-01-23 2010-07-29 Moshe Meir H Therapeutic energy delivery device with rotational mechanism
WO2010093692A2 (en) * 2009-02-10 2010-08-19 Hobbs Eamonn P Irreversible electroporation and tissue regeneration
US8632534B2 (en) 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
USD630321S1 (en) 2009-05-08 2011-01-04 Angio Dynamics, Inc. Probe handle
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
US20110118732A1 (en) 2009-11-19 2011-05-19 The Regents Of The University Of California Controlled irreversible electroporation
CN109112126B (zh) * 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
WO2012051433A2 (en) 2010-10-13 2012-04-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
JP5945597B2 (ja) 2011-07-21 2016-07-05 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジＢｏａｒｄ Ｏｆ Ｓｕｐｅｒｖｉｓｏｒｓ Ｏｆ Ｌｏｕｉｓｉａｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ａｎｄ Ａｇｒｉｃｕｌｔｕｒａｌ Ａｎｄ Ｍｅｃｈａｎｉｃａｌ Ｃｏｌｌｅｇｅ 癌細胞の標的浸透圧溶解
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
ITMO20120015A1 (it) * 2012-01-26 2013-07-27 Guescini Michele Proprieta Al 25 Metodo di perfezionamento per la determinazione quantitativa degli acidi nucleici
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
EP3143124B1 (en) 2014-05-12 2025-01-22 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
WO2016100325A1 (en) 2014-12-15 2016-06-23 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10660691B2 (en) 2015-10-07 2020-05-26 Angiodynamics, Inc. Multiple use subassembly with integrated fluid delivery system for use with single or dual-lumen peristaltic tubing
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
JP7387177B2 (ja) 2017-07-20 2023-11-28 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ パルス磁場勾配を使用する悪性癌細胞の標的化浸透圧溶解
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US12390262B2 (en) 2018-03-13 2025-08-19 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
CN112513273A (zh) 2018-06-22 2021-03-16 豪夫迈·罗氏有限公司 用于调节scn9a表达的寡核苷酸
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US12214189B2 (en) 2019-07-24 2025-02-04 Virginia Tech Intellectual Properties, Inc. Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies
WO2021123086A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for inhibiting scn9a expression
US12485279B2 (en) 2020-11-25 2025-12-02 Virginia Tech Intellectual Properties, Inc. Methods for modulating temporal infrastructure of pulsed electric fields
USD1084316S1 (en) 2023-11-20 2025-07-15 Angiodynamics, Inc. Ferrule

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE209690T1 (de) 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
US5859699A (en) 1997-02-07 1999-01-12 Arcturus Engineering, Inc. Laser capture microdissection analysis vessel
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
GB0021617D0 (en) * 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer

Also Published As

Publication number Publication date
AU2007254583C1 (en) 2011-07-07
US20040146877A1 (en) 2004-07-29
AU2002244862B2 (en) 2007-09-20
WO2002083945A2 (en) 2002-10-24
AU2007254583A1 (en) 2008-01-24
JP2004533239A (ja) 2004-11-04
US20100273866A1 (en) 2010-10-28
US20090074665A1 (en) 2009-03-19
EP1377680A2 (en) 2004-01-07
JP2010063458A (ja) 2010-03-25
CA2443968A1 (en) 2002-10-24
WO2002083945A3 (en) 2003-10-30
EP1377680B1 (en) 2011-10-05
EP2341148A3 (en) 2012-05-30
US7393657B2 (en) 2008-07-01
EP2341148A2 (en) 2011-07-06
ATE527375T1 (de) 2011-10-15
AU2011200879A1 (en) 2011-03-24
AU2007254583B2 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
US7393657B2 (en) Diagnosis and treatment of cancer: I
US7759078B2 (en) Diagnosis and treatment of cancer
AU2002244862A1 (en) Diagnosis and treatment of cancer: I
JP5603145B2 (ja) 疾患のイメージング、診断、及び治療
CN101305020B (zh) 用于诊断和治疗的肿瘤相关抗原的鉴定
EP2688907B1 (en) Dominant negative hsp110 mutant and its use in prognosing and treating cancers
EP3679161A1 (en) Clear cell renal cell carcinoma biomarkers
EP4103752A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
KR20140016230A (ko) 암의 진단 및 치료를 위한 방법 및 화합물
WO1999063110A1 (en) Diagnosis and treatment of cancer
US20060216231A1 (en) Methods for diagnosing and treating tumors and suppressing cd promoters
JP2014507629A (ja) 癌の診断および予後ならびに治療応答予測の新規方法
CN102498219A (zh) 在得自对象的生物学样品中评价癌症的方法
CN116745320A (zh) 诊断或治疗健康状况或优化car-t细胞疗法的治疗功效的方法
WO2008068481A1 (en) New compounds, methods and uses
US20130266936A1 (en) Molecular Markers for the Diagnosis and Treatment of Tumors
JP2007224009A (ja) 癌の予防・治療剤
US20040138161A1 (en) Methods of modulating proliferative conditions
JPWO2005061704A1 (ja) 癌の予防・治療剤
US9233121B2 (en) Compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091016

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100525

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100624

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130702

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees